Ordering Recommendation

Use to screen for mast cell activation disorders, including systemic mastocytosis, using random urine specimens.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha. If possible, discontinue for 2 weeks or 72 hours, respectively, prior to specimen collection.

Collect

Urine.

Specimen Preparation

Transfer 5 mL urine to ARUP standard transport tubes. (Min: 4 mL)
Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.

Storage/Transport Temperature

Refrigerated. Also acceptable: Frozen.

Unacceptable Conditions
Remarks
Stability

Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 1 month

Methodology

Quantitative Liquid Chromatography-Tandem Mass Spectrometry /Colorimetry

Performed

Varies

Reported

6-11 days

Reference Interval

By Report

Interpretive Data



Compliance Category

Performed by non-ARUP Laboratory

Note

Elevated levels of 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG) in urine are not specific for systemic mast cell disease and may be found in patients with angioedema, diffuse urticaria, or myeloproliferative diseases in the absence of diffuse mast cell proliferation.

Hotline History

N/A

CPT Codes

84150; 82570

Components

Component Test Code* Component Chart Name LOINC
3004161 2,3 Dinor-11Beta-Prostaglandin F2a, U 97658-9
3004162 Creatinine, Random Urine 2161-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • 11 Beta-Prostaglandin F2 Alpha
  • 11BPG
  • 2, 3 11 Beta-Prostaglandin F2 Alpha
  • 23BPG
  • BPG2
  • Mastocytosis
  • Prostaglandin
2,3 Dinor-11Beta-Prostaglandin F2 Alpha, Random Urine

Mayo Clinic Laboratories